#118649
Re: Farmas USA
BLUE
-We are a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer.
-September 22, 2017, Celgene exercised its option to obtain an exclusive worldwide license to develop and commercialize bb21217, the second optioned product candidate,
-A Share Purchase Agreement (“SPA”) was entered into by the parties on August 3, 2018. the Company issued Regeneron 0.4 million shares of the Company’s common stock, subject to certain restrictions, for $238.10 per share, or $100.0 million in the aggregate. The purchase price represents $63.0 million worth of common stock plus a $37.0 million premium,
September 30, 2019, we had cash of approximately $1.41 billion. We expect that our existing cash, will be sufficient to 2022.
Pipeline ( una ya aprovaba en europa)
-We are a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer.
-September 22, 2017, Celgene exercised its option to obtain an exclusive worldwide license to develop and commercialize bb21217, the second optioned product candidate,
-A Share Purchase Agreement (“SPA”) was entered into by the parties on August 3, 2018. the Company issued Regeneron 0.4 million shares of the Company’s common stock, subject to certain restrictions, for $238.10 per share, or $100.0 million in the aggregate. The purchase price represents $63.0 million worth of common stock plus a $37.0 million premium,
September 30, 2019, we had cash of approximately $1.41 billion. We expect that our existing cash, will be sufficient to 2022.
Pipeline ( una ya aprovaba en europa)